GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Thanks for your post. There sure are a lot of CD20 programs out there, which is not surprising given what a success Rituxan has been.

It will be interesting to see which CD20 programs make it to market and become commercial hits. I don’t think GTC has shown enough cards yet for investors to handicap the likelihood that GTC’s CD20 program will bear fruit.